Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Ins3.2
Insulin (Bodybuilding-Verwendung) – Forschung
Überwiegend Mechanismus / Beobachtung
6 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Insulin (Bodybuilding-Verwendung) sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus gemischt-qualitativen Meta-Analysen und randomisierten Studien, veröffentlicht 1987–2019 mit einer typischen Studiengröße von 173 Teilnehmenden.
Basierend auf 6 Studien · 1 Meta-Analyse · 1 RCT · 180 Teilnehmende insgesamt
Konfidenz
Mittlere Konfidenz
Nach Outcome
Muscle protein & lean mass (claimed)Antikatabol (verbessert die Netto-Muskelproteinbilanz), aber ohne nachgewiesenen Muskel- oder Leistungsvorteil bei gesunden Sportlern — und die Off-Label-Anwendung birgt das Risiko schwerer, mitunter tödlicher Hypoglykämien. · Für den Einsatz zum Muskelaufbau nicht belegt
Überwiegend Mechanismus / Beobachtung4 Studien
Glucose & hypoglycemiaEin echtes blutzuckersenkendes Hormon, das medizinisch bei Diabetes eingesetzt wird; hier nur zu Informationszwecken aufgeführt — die eigenständige Dosierung ohne ärztliche Aufsicht birgt das Risiko einer tödlichen Hypoglykämie. · Akut (medizinische Anwendung)
Überwiegend Mechanismus / Beobachtung4 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung4 Studien
Ältere Forschungsbasis
Neueste Studie von 2019 · Neueste Meta-Analyse: 2016
198720032019
1Meta-Analysen=173 · medium study2016
Insulin did not affect MPS (WMD 3.90 [95% CI -0.74, 8.55], p = 0.71), but significantly reduced MPB (WMD -15.46 [95% CI -19.74, -11.18], p < 0.001).
Abdulla H, Smith K, Atherton PJ, Idris I. · Diabetologia (2016)
Systematic review and meta-analysis of insulin-infusion studies (44 studies reviewed, 25 meta-analyzed, 173 individuals) examining insulin's effect on muscle-protein synthesis (MPS) and breakdown (MPB)
Insulin did NOT significantly increase muscle-protein synthesis; it significantly REDUCED protein breakdown, improving net protein balance — i.e. its muscle action is anti-catabolic, not strongly anabolic
The synthesis effect was permissive and dependent on amino-acid availability — insulin alone, without extra amino acids, does not drive new muscle protein
In response to forearm hyperinsulinemia ... the net balance of phenylalanine and leucine became positive ... Despite the marked increase in net balance, the tissue Rd [synthesis] ... was unchanged.
Gelfand RA, Barrett EJ. · The Journal of clinical investigation (1987)
Classic human forearm-perfusion study in seven normal men measuring amino-acid kinetics across muscle before and during a physiologic insulin infusion
Insulin shifted muscle into net positive protein balance — but did so by suppressing protein breakdown (release), with little change in protein synthesis (disposal)
Foundational mechanistic evidence that insulin's anabolic action on human muscle is primarily ANTI-CATABOLIC
They have been strictly associated with serious adverse effects ... the short- as well as long-term consequences of such habits remain largely unrecognized.
Imperlini E, Mancini A, Alfieri A, Martone D, Caterino M, Orrù S, Buono P. · Molecular bioSystems (2015)
Review of the molecular harms of supraphysiologic performance-enhancing drug use, covering anabolic-androgenic steroids and peptide hormones (growth hormone and IGF-1) used for body shaping
Frames the broader metabolic and organ harm of supraphysiologic doping-agent misuse — the polypharmacy context in which insulin is typically used
Underscores that body-shaping drug misuse carries serious, often underrecognized adverse consequences, with no offsetting controlled performance benefit
A theoretical benefit of insulin abuse by body builders is that it is undetectable by currently available tests. A case is presented that highlights the dangers of such abuse.
Evans PJ, Lynch RM. · British journal of sports medicine (2003)
The field-defining report naming insulin as a drug of abuse in bodybuilding, presenting a case that highlights the dangers
Documents the key reason for misuse — insulin is undetectable by standard anti-doping tests — and the corresponding hazard
Establishes insulin abuse as a recognized, dangerous practice in strength sport rather than a fringe anecdote
We discuss the case of a 30-year-old male bodybuilder presenting with coma due to severe hypoglycemia ... subsequently found to be related to cryptic insulin injections.
Heidet M, Abdel Wahab A, Ebadi V, Cogne Y, Chollet-Xemard C, Khellaf M. · The Journal of emergency medicine (2019)
Case report of a 30-year-old male bodybuilder in coma from severe hypoglycemia, requiring iterative (repeated) glucose infusions, ultimately traced to surreptitious insulin injection
Warns emergency physicians that exogenous insulin injected as an ergogenic aid is a real cause of unexplained coma in strength athletes
The lethal-harm anchor: documents how non-medical insulin use lands a healthy young athlete in hypoglycemic coma needing intensive care
He injected 70 IE of a short-acting insulin subcutaneously, resulting in severe hypoglycaemia ... he lost consciousness and showed signs of convulsions.
Konrad C, Schüpfer G, Wietlisbach M, Gerber H. · Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie (1998)
Case report of a 30-year-old male bodybuilder who injected 70 IU of short-acting insulin to 'stimulate muscle growth' before a competition and developed severe hypoglycemia
He lost consciousness and convulsed; glucose remained low despite IV glucose and required glucagon plus intensive-care stabilization
An earlier, independent case confirming the same pattern — non-medical insulin in a bodybuilder causing life-threatening hypoglycemia